Levodopa therapy with entacapone in daily clinical practice: Results of a post-marketing surveillance study

Current Medical Research and Opinion

Volumn 20, Issue 1, 2004, Pages 115-120

  Kupsch, Andreas ^a,c   Trottenberg, Thomas ^a   Bremen, Dirk ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Orion Pharma GmbH   (Germany)

^c HUMBOLDT UNIVERSITY   (Germany)

Author keywords

COMT inhibition; Entacapone; Levodopa; Parkinson's disease

Indexed keywords

AMANTADINE; BENSERAZIDE; BENSERAZIDE PLUS LEVODOPA; BUDIPINE; CARBIDOPA; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPA DECARBOXYLASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; LEVODOPA; MONOAMINE OXIDASE B INHIBITOR;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CHRONOPHARMACOLOGY; CLINICAL PRACTICE; CLINICAL TRIAL; DIARRHEA; DOSE TIME EFFECT RELATION; DRUG INDICATION; DRUG MARKETING; DRUG POTENCY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; DRUG TOLERANCE; DRUG WITHDRAWAL; DYSKINESIA; FEMALE; HALLUCINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PARKINSON DISEASE; POSTMARKETING SURVEILLANCE; RISK BENEFIT ANALYSIS; SENSORY DYSFUNCTION; SIDE EFFECT; SYMPTOMATOLOGY; VERTIGO;

ADULT; AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; CATECHOLS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; PATIENT SATISFACTION; PRODUCT SURVEILLANCE, POSTMARKETING; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 0345798144     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079903125002775     Document Type: Article

References (15)

1. Miyasaki JM, Martin W, Suchowersky O, Weiner WJ, Lang AE. Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2002;58:11-7
2. Rascol O, Goetz C, Koller W, Poewe W, Sampaio C. Treatment interventions for Parkinson's disease: an evidence based assessment. Lancet 2002;359:1589-98
3. Rajput AH. Levodopa prolongs life expectancy and is non-toxic to substantia nigra. Parkinsonism Relat Disord 2001;8:95-100
4. Marsden CD, Parkes JD. 'On-off' effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet 1976;1:292-6
5. Keranen T, Gordin A, Harjola VP, Karlsson M, Korpela K, Pentikainen PJ, Rita H, Seppala L, Wikberg T. The effect of catechol-O-methyltransferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers. Clin Neuropharmacol 1993:16;145-56
6. Merello M, Lees AJ, Webster R, Bovingdon M, Gordin A. Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1994;57:186-9
7. Ruottinen HM, Rinne UK. A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson's disease. Clin Neuropharmacol 1996;19:283-96
8. Ruottinen, HM, Rinne, UK. Effect of one month's treatment with peripherally acting catechol-O-methyltransferase inhibitor, entacapone, on pharmacokinetics and motor response to levodopa in advanced parkinsonian patients. Clin Neuropharmacol 1996;19:222-33
9. Parkinson Study Group. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Ann Neurol 1997;42:747-55
10. Rinne UK, Larsen JP, Siden A, Worm-Petersen J, the Nomecomt Study Group. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Neurology 1998;51:1309-14
11. Ruottinen HM, Rinne UK. Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations. J Neurol Neurosurg Psychiatry 1996;60:36-40
12. Brooks D, Sagar H and the UK-Irish Entacapone Study group. Entacapone is beneficial in both bluctuating and non-fluctuating patients with Parkinson's disease. A randomized, placebo-controlled, double-blind six-month study. J Neurol Neurosurg Psychiatry 2003;74:1071-9
13. Myllylä VV, Kultalahti ER, Haapaniemi H, Leinonen M. Twelve-month safety of entacapone in patients with Parkinson's disease. Eur J Neurol 2001;8:53-60
14. Poewe W, Deuschl G, Gordin A and Celomen Study Group. Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a six-months randomized placebo-controlled double-blind study in Germany and Austria. Acta Neurol Scand 2002;105:245-55
15. Wheatley K, Stowe RL, Clarke CE, Hills RK, Williams AC, Gray R. Evaluating drug treatments for Parkinson's disease: how good are the trials? Br Med J 2002;324:1508-11